Academic Journal
Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
| العنوان: | Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial |
|---|---|
| المؤلفون: | DiNardo, Courtney D., de Botton, Stéphane, Risueño, Alberto, Schuh, Andre C., Löwenberg, Bob, Kim, Hee-Je, Vyas, Paresh, Wei, Andrew H., Stein, Eytan M., Döhner, Hartmut, Fathi, Amir T., Martin-Regueira, Patricia, Taningco, Lilia, Bluemmert, Iryna, Yu, Xin, See, Wendy L., Hasan, Maroof |
| المصدر: | Clinical Lymphoma Myeloma and Leukemia ; volume 22, page S124 ; ISSN 2152-2650 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/s2152-2650(22)00742-x |
| الاتاحة: | http://dx.doi.org/10.1016/s2152-2650(22)00742-x https://api.elsevier.com/content/article/PII:S215226502200742X?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S215226502200742X?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; https://doi.org/10.15223/policy-017 ; https://doi.org/10.15223/policy-037 ; https://doi.org/10.15223/policy-012 ; https://doi.org/10.15223/policy-029 ; https://doi.org/10.15223/policy-004 |
| رقم الانضمام: | edsbas.D2C676F8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/s2152-2650(22)00742-x |
|---|